Page results
-
Ensuring that UCLH staff understand the urgency of the climate crisis and support our net zero programme is crucial if we want to be successful in reaching our goal of net zero carbon emissions by 2031. Our patients must be kept informed of changes and we must work closely with other NHS organisations, including NHS England, if we are to deliver a successful programme. This page documents our progress to date.
-
Medtronic are discontinuing the MiniMed™ Mio™ Infusion sets. If you are currently using MiniMed™ Mio™ infusion sets, you will need to change to an alternative infusion set before 31 March 2023. After this date, MiniMed™ Mio™ infusion sets will no longer be available.
-
Preterm infants do not get used to repeated pain in the way that full-term infants, children and adults do habituate to pain, finds a study at UCLH and UCL.
-
Well done to everyone who ran to support UCLH in the iconic London Landmarks Half Marathon on 2 April!
-
A large study looking at the experiences of people across England after giving birth by Caesarean section has highlighted disparities in outcomes between patients of different ethnic groups.
-
The UCLH@Home service is helping patients like 80-year-old Margaret Stone to continue their recovery in their own home under the care of their hospital team.
-
Experts from across the world, led by UCLH and UCL clinicians and scientists, have created a framework to guide the introduction of new and advanced robots for surgical procedures.
-
A new research study at UCLH and UCL will investigate how a rare type of blood cancer develops and what types of treatment may be effective for patients.
-
From the 23rd January, there will be a staggered rollout of the Tandem t:slim™ 7.7 Control IQ software.
-
UCLH research manager Sarah Taylor has won a national leadership award for her work to develop and train research staff.
File results
-
FOI/2022/0209 - Patient tracking list or waiting lists
-
FOI/2022/0211 - Enteral feeding machine mechanical insufflator
-
FOI/2022/0212 - Clotting disorders medication
-
FOI/2022/0214 - Prostate Cancer (Summary Funding and costs of Xtandi (Enzalutamide) trial: NCT00974311) Xtandi (Enzalutamide) trial, NCT00974311
-
FOI/2022/0217 - Medications for dermatological conditions
-
FOI/2022/0221 - Asthma medications
-
FOI/2022/0223 - Policies/ procedures for management of patients with chest pain
-
FOI/2022/0224 - Procurement for physiotherapy, occupational therapy, pharmacy, radiography, speech and language therapy and sterile services
-
FOI/2022/0226 - Treatments for Haemophilia A
-
FOI/2022/0227 - Number of cancer trackers and cancer MDT co-ordinators at Trust